Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
about
Evaluation of BM cytomorphology after allo-SCT in patients with AML.Back to the future! The evolving role of maintenance therapy after hematopoietic stem cell transplantation.Kinetics of IL-7 and IL-15 levels after allogeneic peripheral blood stem cell transplantation following nonmyeloablative conditioningDetection and preliminary characterization of CD8+T lymphocytes specific for Wilms' tumor antigen in patients with non-Hodgkin lymphoma.Real-time assessment of relapse risk based on the WT1 marker in acute leukemia and myelodysplastic syndrome patients after hematopoietic cell transplantationA multigene array for measurable residual disease detection in AML patients undergoing SCTDonor Chimerism of B Cells and Nature Killer Cells Provides Useful Information to Predict Hematologic Relapse following Allogeneic Hematopoietic Stem Cell Transplantation.Donor chimerism early after reduced-intensity conditioning hematopoietic stem cell transplantation predicts relapse and survivalMixed T Lymphocyte Chimerism after Allogeneic Hematopoietic Transplantation Is Predictive for Relapse of Acute Myeloid Leukemia and Myelodysplastic Syndromes.Induction of WT1-specific human CD8+ T cells from human HSCs in HLA class I Tg NOD/SCID/IL2rgKO mice.Minimal residual disease testing to predict relapse following transplant for AML and high-grade myelodysplastic syndromes.Promising role of reduced-toxicity hematopoietic stem cell transplantation (PART-I).Relapse assessment following allogeneic SCT in patients with MDS and AML.Immune responses to WT1 in patients with AML or MDS after chemotherapy and allogeneic stem cell transplantation.Sorafenib and azacitidine as salvage therapy for relapse of FLT3-ITD mutated AML after allo-SCT.Monitoring of acute myeloid leukemia patients after allogeneic stem cell transplantation employing semi-automated CD34+ donor cell chimerism analysis.Acute GVHD is a strong predictor of full donor CD3+ T cell chimerism after reduced intensity conditioning allogeneic stem cell transplantation.Outcome of allogeneic hematopoietic stem cell transplantation for cytogenetically normal AML and identification of high-risk subgroup using WT1 expression in association with NPM1 and FLT3-ITD mutations.Detection of relapse after hematopoietic stem cell transplantation in childhood by monitoring of WT1 expression and chimerism.Simultaneous analysis of the expression of 14 genes with individual prognostic value in myelodysplastic syndrome patients at diagnosis: WT1 detection in peripheral blood adversely affects survival
P2860
Q30318110-C117C872-193E-4250-80B7-B9714BE96E7EQ34380489-A3332A9A-DF6B-444B-B3A0-A86E1DD51287Q34598248-BF3A689E-B3F5-4317-9B45-B6D24A1C6AA0Q34616701-7100A32C-45E6-44B5-9565-AAA966A8AFE6Q34861985-23BABB5A-9319-448E-8E5E-144B3B81D96CQ35582360-1714B34C-D958-4902-9856-B1F378079031Q35726470-D4552C30-974A-462D-96CE-1FE10221FFD1Q35769347-0466B599-4D90-467D-8C80-6064FFBED8B0Q36157233-0C4E794E-31E6-4D98-B04E-CDB687A5B692Q36572920-724E2D54-3F81-4907-A003-EBA06083AE42Q37872296-718EFAAF-5A31-44EE-99DA-08230BCF80CBQ38029953-66D2F63B-FD8B-4C2A-9AD3-59454B582A8AQ38199623-2D32C9F5-FFFD-413A-8FD7-ADFAFC36E69AQ38947873-169E0512-9DBC-4014-9005-8427A5FC5DBCQ40454294-48E594C3-8738-476E-937C-41CD0A18AA29Q43879358-370754F6-56D0-4173-8A82-2A1C0BD36086Q47236287-0518F367-0ACE-49A1-A180-0E2972777E0CQ52938002-CE73878B-B2D8-42AB-9333-9E224CBB81C3Q53629618-937844CA-F089-451C-B52E-3C288FE300F7Q58865825-B4FB1983-E3C0-4AEC-9BF8-E72573040E85
P2860
Monitoring of WT1 expression in PB and CD34(+) donor chimerism of BM predicts early relapse in AML and MDS patients after hematopoietic cell transplantation with reduced-intensity conditioning.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh
2010年學術文章
@zh-hant
name
Monitoring of WT1 expression in PB and CD34
@nl
Monitoring of WT1 expression i ...... educed-intensity conditioning.
@en
type
label
Monitoring of WT1 expression in PB and CD34
@nl
Monitoring of WT1 expression i ...... educed-intensity conditioning.
@en
prefLabel
Monitoring of WT1 expression in PB and CD34
@nl
Monitoring of WT1 expression i ...... educed-intensity conditioning.
@en
P2093
P2860
P356
P1433
P1476
Monitoring of WT1 expression i ...... educed-intensity conditioning.
@en
P2093
D Niederwieser
G-N Franke
H K Al-Ali
J Edelmann
S Leiblein
P2860
P2888
P304
P356
10.1038/LEU.2010.283
P577
2010-12-07T00:00:00Z